RIVANNA Expands Accuro XV Clinical Program Across Major U.S. Academic Medical Centers

According to a recent LinkedIn post from RIVANNA, the company’s clinical program for its Accuro XV portable ultrasound system has expanded from two to eight U.S. sites in four months, with 10 systems deployed at major academic medical centers. The sites include Denver Health, Texas Tech Health El Paso, UCSF, University of Utah, UVA Health, UT Southwestern, Virginia Commonwealth University, and Yale, and all are reported to be actively enrolling patients.

The post indicates that Accuro XV, a point-of-care volumetric ultrasound platform aimed at fracture evaluation in emergency settings, is being used to develop AI-enabled fracture detection capabilities that may accelerate the anticipated 510(k) submission timeline. RIVANNA’s update notes 666 patients enrolled to date and suggests preliminary, unpublished analysis points to potential patient-experience benefits, which, if validated, could support clinical adoption and reimbursement discussions.

The post further links this expansion to the execution of a funding option by BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. For investors, the involvement of BARDA and the concentration of trials at leading academic centers may signal institutional validation and de-risk aspects of product development, potentially strengthening RIVANNA’s position in the MedTech and emergency medicine imaging markets if regulatory and clinical milestones are achieved.